Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin

This publication has 22 references indexed in Scilit:

• Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
  JAMA, 1996
• Effect of fluvastatin on intermediatedensity Lipoprotein (remnants) and other lipoprotein levels in hypercholestarolemia
  The American Journal of Cardiology, 1995
• Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety
  The American Journal of Cardiology, 1994
• Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins
  Journal of Lipid Research, 1993
• Effects of lovastatin on the levels, structure, and atherogenicity of VLDL in patients with moderate hypertriglyceridemia.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
• Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B‐containing lipoproteins
  Journal of Internal Medicine, 1990
• Effect of fibric acid derivatives on blood lipid and lipoprotein levels
  The American Journal of Medicine, 1987
• Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
  Journal of Clinical Investigation, 1986
• Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.
  Journal of Clinical Investigation, 1985